作者
Fahad Quhal, Keiichiro Mori, Andreas Bruchbacher, Irene Resch, Hadi Mostafaei, Benjamin Pradere, Victor M Schuettfort, Ekaterina Laukhtina, Shin Egawa, Harun Fajkovic, Mesut Remzi, Shahrokh F Shariat, Manuela Schmidinger
发表日期
2021/10/1
来源
European urology oncology
卷号
4
期号
5
页码范围
755-765
出版商
Elsevier
简介
Context
There have been substantial changes in the management of patients with metastatic renal cell carcinoma (mRCC) over the past decade, with upfront immunotherapy-based combinations replacing targeted therapies. A broad range of combinations have been approved, and comparisons of their efficacy and safety are needed to guide the optimal choice of first-line therapy.
Objective
To perform indirect comparisons of efficacy and safety of first-line immune checkpoint inhibitor (ICI)-based combination therapies for mRCC.
Evidence acquisition
We searched multiple databases and abstracts of major scientific meetings up to February 2021 to identify phase III randomized controlled trials of patients receiving first-line ICI-based combination therapies for mRCC. Progression-free survival (PFS) and overall survival (OS) were the primary endpoints. The secondary endpoints included complete response rates (CRRs …
学术搜索中的文章
F Quhal, K Mori, A Bruchbacher, I Resch, H Mostafaei… - European Urology Oncology, 2021